PMEL and melanoma: This monoclonal antibody that stains glycoproteins (gp100, Pmel17) between the junctional nevus cells and melanoma has a sensitivity of between 66 and 97%, especially in a primary lesion, with a lesser sensitivity for its metastatic variant.